Centre for Sight Medical Director presented study results on novel Nasal Spray for the treatment of Dry Eye at the recent ESCRS meeting in Amsterdam.
A nasal spray that increases the patient’s own tear production has just been approved by the FDA in the United States. Unfortunately, this is not currently available in the UK and Europe but hopefully will be in due course.
Medical Director of Centre for Sight, Sheraz Daya who is also a consultant for Oyster Point Pharma presented the results of FDA trials at the recent European Society of Cataract and Refractive Surgery meeting in Amsterdam. The presentation was well received and as Mr Daya states, “this drug holds great promise in the treatment of dry eye”. He emphasised the point that natural tears contain numerous growth factors and over 1500 proteins all of benefit to the ocular surface and way better than any tear substitute.
For more on this new drug OC-1 or Tyrvaya
